FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017020511> ?p ?o ?g. }

• W2017020511 endingPage "1354" @default.
• W2017020511 startingPage "1343" @default.
• W2017020511 abstract "Background In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are not currently recommended for individuals with KRAS mutant tumours. This is based on subgroup analyses of individual clinical trials rather than a formal synthesis of evidence for KRAS status as a predictive biomarker, while newer trials report no benefit for anti-EGFR antibodies irrespective of KRAS status. This study systematically reviewed the evidence for KRAS mutation status as a treatment effect modifier of response to anti-EGFR antibodies and the influence of partner chemotherapy. Methods Medline (1966–2010), EMBASE and American and European oncology meeting abstracts were searched for randomised controlled trials reporting the influence of KRAS status on effectiveness of anti-EGFR antibodies in metastatic CRC. The treatment efficacy was summarised by KRAS status using hazard ratios (HR) for progression-free survival (PFS) and risk differences (RD) for objective response. For each study, a measure of effect modification was calculated, and aggregated using random effects meta-analysis to assess the interaction between KRAS and treatment effect. Findings Eleven studies (8924 patients) were selected from 198 reports. Two studies assessed anti-EGFR antibodies as monotherapy and nine their use with chemotherapy. KRAS status was reported in 7555 cases. In subgroup analysis, the progression HR for KRAS wild patients assigned to anti-EGFR antibodies was 0.80 (4436 patients 95%CI: 0.64, 0.99) and for mutant cases 1.11 (3119 patients, 95%CI: 0.97, 1.27). A significant treatment effect interaction between KRAS status and addition of anti-EGFR antibodies to standard treatment was found for PFS (ratio of HRs 0.71, 95%CI: 0.57, 0.90 p = 0.005) and response rate difference (difference in RDs 15%, 95%CI: 8, 22%, p < 0.001). There was no evidence that the extent of effect modification differed between chemotherapeutic partners for both PFS (p = 0.3) and response rate (p = 0.6). Interpretation KRAS mutation status is a treatment effect modifier for anti-EGFR antibodies in metastatic CRC. Further evidence is needed to determine whether this is true for all chemotherapy partners and all clinical circumstances." @default.
• W2017020511 created "2016-06-24" @default.
• W2017020511 creator A5003569285 @default.
• W2017020511 creator A5008087173 @default.
• W2017020511 creator A5013886789 @default.
• W2017020511 creator A5052741565 @default.
• W2017020511 creator A5074700925 @default.
• W2017020511 date "2011-06-01" @default.
• W2017020511 modified "2023-09-27" @default.
• W2017020511 title "A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer" @default.
• W2017020511 cites W1592228396 @default.
• W2017020511 cites W1971366462 @default.
• W2017020511 cites W1973105854 @default.
• W2017020511 cites W1974365898 @default.
• W2017020511 cites W1999250974 @default.
• W2017020511 cites W2002226820 @default.
• W2017020511 cites W2028892936 @default.
• W2017020511 cites W2087088052 @default.
• W2017020511 cites W2088095316 @default.
• W2017020511 cites W2095201384 @default.
• W2017020511 cites W2095702029 @default.
• W2017020511 cites W2096491867 @default.
• W2017020511 cites W2097121246 @default.
• W2017020511 cites W2098354753 @default.
• W2017020511 cites W2098931866 @default.
• W2017020511 cites W2104580737 @default.
• W2017020511 cites W2106789440 @default.
• W2017020511 cites W2125435699 @default.
• W2017020511 cites W2127640925 @default.
• W2017020511 cites W2135800465 @default.
• W2017020511 cites W2136184341 @default.
• W2017020511 cites W2136509556 @default.
• W2017020511 cites W2144425748 @default.
• W2017020511 cites W2148173212 @default.
• W2017020511 cites W2149469912 @default.
• W2017020511 cites W2155311724 @default.
• W2017020511 cites W2158863975 @default.
• W2017020511 cites W2162176062 @default.
• W2017020511 cites W2164837623 @default.
• W2017020511 cites W2167539263 @default.
• W2017020511 cites W2168377135 @default.
• W2017020511 cites W2207361566 @default.
• W2017020511 cites W2409420104 @default.
• W2017020511 cites W4233616171 @default.
• W2017020511 cites W4385789423 @default.
• W2017020511 doi "https://doi.org/10.1016/j.ejca.2011.03.031" @default.
• W2017020511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21550229" @default.
• W2017020511 hasPublicationYear "2011" @default.
• W2017020511 type Work @default.
• W2017020511 sameAs 2017020511 @default.
• W2017020511 citedByCount "63" @default.
• W2017020511 countsByYear W20170205112012 @default.
• W2017020511 countsByYear W20170205112013 @default.
• W2017020511 countsByYear W20170205112014 @default.
• W2017020511 countsByYear W20170205112015 @default.
• W2017020511 countsByYear W20170205112016 @default.
• W2017020511 countsByYear W20170205112017 @default.
• W2017020511 countsByYear W20170205112018 @default.
• W2017020511 countsByYear W20170205112019 @default.
• W2017020511 countsByYear W20170205112020 @default.
• W2017020511 countsByYear W20170205112021 @default.
• W2017020511 countsByYear W20170205112022 @default.
• W2017020511 countsByYear W20170205112023 @default.
• W2017020511 crossrefType "journal-article" @default.
• W2017020511 hasAuthorship W2017020511A5003569285 @default.
• W2017020511 hasAuthorship W2017020511A5008087173 @default.
• W2017020511 hasAuthorship W2017020511A5013886789 @default.
• W2017020511 hasAuthorship W2017020511A5052741565 @default.
• W2017020511 hasAuthorship W2017020511A5074700925 @default.
• W2017020511 hasConcept C121608353 @default.
• W2017020511 hasConcept C126322002 @default.
• W2017020511 hasConcept C143998085 @default.
• W2017020511 hasConcept C168563851 @default.
• W2017020511 hasConcept C187960798 @default.
• W2017020511 hasConcept C207103383 @default.
• W2017020511 hasConcept C2776694085 @default.
• W2017020511 hasConcept C2778332735 @default.
• W2017020511 hasConcept C2779998722 @default.
• W2017020511 hasConcept C2781187634 @default.
• W2017020511 hasConcept C44249647 @default.
• W2017020511 hasConcept C526805850 @default.
• W2017020511 hasConcept C71924100 @default.
• W2017020511 hasConcept C95190672 @default.
• W2017020511 hasConceptScore W2017020511C121608353 @default.
• W2017020511 hasConceptScore W2017020511C126322002 @default.
• W2017020511 hasConceptScore W2017020511C143998085 @default.
• W2017020511 hasConceptScore W2017020511C168563851 @default.
• W2017020511 hasConceptScore W2017020511C187960798 @default.
• W2017020511 hasConceptScore W2017020511C207103383 @default.
• W2017020511 hasConceptScore W2017020511C2776694085 @default.
• W2017020511 hasConceptScore W2017020511C2778332735 @default.
• W2017020511 hasConceptScore W2017020511C2779998722 @default.
• W2017020511 hasConceptScore W2017020511C2781187634 @default.
• W2017020511 hasConceptScore W2017020511C44249647 @default.
• W2017020511 hasConceptScore W2017020511C526805850 @default.
• W2017020511 hasConceptScore W2017020511C71924100 @default.
• W2017020511 hasConceptScore W2017020511C95190672 @default.
• W2017020511 hasFunder F4320320501 @default.

• next